To evaluate the efficacy of VIB4920 antoagonism of CD40L in achieving a complete renal response in active lupus nephritis
A double-blind, placebo-controlled trial of investigational agent combined with MMF.
SLE; age 18 or older UPCR ≥ 1.0 based on a 24-hour urine collection at Visit -1. Renal biopsy within 24 weeks prior to Visit -1 of ISN/RPS LN [5, 6] with both of the following: a. Class III, Class IV, or Class V in combination with Class III or IV, and b. Modified NIH Activity Index ≥ 1.
Principal Investigator